| payload |
{"created_at":"2026-04-13T02:56:12.998 {"created_at":"2026-04-13T02:56:12.998484+00:00","signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/gsk-announces-positive-phase-i-results-mo-rez-ovarian-and-endometrial-cancer","value":{"fp":"f6b198d72d95a1e8","kind":"unusual_volume","published_at":"2026-04-13T01:46:18+00:00","source":"Nasdaq Markets","summary":"(RTTNews) - GSK plc (GSK, GSK.L) announced encouraging findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. At the highest doses evaluated, Mo-Rez monotherapy achieved confir","tickers":["ADC"],"title":"GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer","url":"https://www.nasdaq.com/articles/gsk-announces-positive-phase-i-results-mo-rez-ovarian-and-endometrial-cancer"}}... |